BNP Paribas Financial Markets’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-14,600
| Closed | -$693K | – | 5733 |
|
|
2025
Q3 | $693K | Buy |
14,600
+7,125
| +95% | +$345K | ﹤0.01% | 3386 |
|
|
2025
Q2 | $399K | Buy |
7,475
+2,389
| +47% | +$109K | ﹤0.01% | 3468 |
|
|
2025
Q1 | $206K | Sell |
5,086
-3,396
| -40% | -$144K | ﹤0.01% | 3676 |
|
|
2024
Q4 | $236K | Sell |
8,482
-12,220
| -59% | -$370K | ﹤0.01% | 3769 |
|
|
2024
Q3 | $594K | Sell |
20,702
-8,370
| -29% | -$218K | ﹤0.01% | 2787 |
|
|
2024
Q2 | $682K | Sell |
29,072
-30,222
| -51% | -$646K | ﹤0.01% | 2492 |
|
|
2024
Q1 | $1.5M | Sell |
59,294
-152,918
| -72% | -$3.67M | ﹤0.01% | 2237 |
|
|
2023
Q4 | $4.96M | Buy |
212,212
+152,691
| +257% | +$3.01M | 0.01% | 1409 |
|
|
2023
Q3 | $3.01M | Buy |
59,521
+24,047
| +68% | +$1.12M | ﹤0.01% | 1621 |
|
|
2023
Q2 | $1.66M | Sell |
35,474
-29,043
| -45% | -$1.33M | ﹤0.01% | 1868 |
|
|
2023
Q1 | $2.47M | Buy |
64,517
+26,757
| +71% | +$1.19M | ﹤0.01% | 1676 |
|
|
2022
Q4 | $2.07M | Buy |
37,760
+23,142
| +158% | +$992K | ﹤0.01% | 1737 |
|
|
2022
Q3 | $498K | Sell |
14,618
-7,780
| -35% | -$119K | ﹤0.01% | 2983 |
|
|
2022
Q2 | $212K | Buy |
22,398
+15,817
| +240% | +$165K | ﹤0.01% | 3061 |
|
|
2022
Q1 | $93.4K | Buy |
6,581
+885
| +16% | +$15.5K | ﹤0.01% | 3372 |
|
|
2021
Q4 | $120K | Buy |
5,696
+898
| +19% | +$19.9K | ﹤0.01% | 3542 |
|
|
2021
Q3 | $107K | Buy |
4,798
+3,857
| +410% | +$87.3K | ﹤0.01% | 3244 |
|
|
2021
Q2 | $23.3K | Sell |
941
-781
| -45% | -$21.9K | ﹤0.01% | 3495 |
|
|
2021
Q1 | $50K | Buy |
1,722
+393
| +30% | +$11.9K | ﹤0.01% | 3608 |
|
|
2020
Q4 | $34.3K | Sell |
1,329
-1,752
| -57% | -$48.7K | ﹤0.01% | 3706 |
|
|
2020
Q3 | $94.9K | Buy |
3,081
+2,651
| +617% | +$92.6K | ﹤0.01% | 3145 |
|
|
2020
Q2 | $10.7K | Sell |
430
-2,045
| -83% | -$46.7K | ﹤0.01% | 3679 |
|
|
2020
Q1 | $52.5K | Buy |
2,475
+1,913
| +340% | +$41K | ﹤0.01% | 3513 |
|
|
2019
Q4 | $12.5K | Sell |
562
-42
| -7% | -$869 | ﹤0.01% | 4101 |
|
|
2019
Q3 | $13.7K | Buy |
+604
| New | +$14.1K | ﹤0.01% | 4089 |
|
Other funds holding AKRO
BNP Paribas Financial Markets's AKRO Position: Q4 2025 in Review
BNP Paribas Financial Markets sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 14,600 shares — an estimated $693K sold.
BNP Paribas Financial Markets first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $4.96M in Q4 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- BNP Paribas Financial Markets reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- BNP Paribas Financial Markets sold 14,600 Akero Therapeutics shares in Q4 2025, an estimated $693K.
- BNP Paribas Financial Markets first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- BNP Paribas Financial Markets's Akero Therapeutics position peaked at $4.96M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2025, filed 10 Feb 2026.